Furthermore, AML patients with CD56neg CD16+ NK cells expansion displayed increased frequency of terminally mature CD57+ KIR+ CD56neg CD16+ NK cells compared to HV or/and patients without expansion. This evidence concerns the gene B3GAT1 and acute myeloid leukemia.